Pierian Spring

GenomOncology Welcomes Garreth Hippe as Chief Commercial Officer

Retrieved on: 
Tuesday, October 3, 2023
Garreth O'Connor, Genomics, Acquisition, Standard of care, Medicine, Growth, Patient, Oracle Health Sciences, Management, Pharma, Physician, Pierian Spring, Elsevier

CLEVELAND, Oct. 3, 2023 /PRNewswire/ -- GenomOncology, a prominent precision oncology software company, announced today the appointment of Garreth Hippe as Chief Commercial Officer.

Key Points: 
  • CLEVELAND, Oct. 3, 2023 /PRNewswire/ -- GenomOncology, a prominent precision oncology software company, announced today the appointment of Garreth Hippe as Chief Commercial Officer.
  • GenomOncology announced today the appointment of Garreth Hippe as Chief Commercial Officer.
  • I am excited and proud to be part of the GenomOncology team, which has the broad portfolio of technology-driven software solutions that are making this a reality by advancing precision medicine programs at institutions and partners throughout the world," emphasized Garreth Hippe, the newly appointed Chief Commercial Officer at GenomOncology.
  • Brad Wertz, Chief Executive Officer at GenomOncology, expressed enthusiasm about Garreth Hippe's addition to the team, highlighting his role in expanding the platform's reach.

Arima Genomics and Velsera Announce Partnership to Enable Broad Adoption of Arima Gene Fusion Test in Clinical Laboratories

Retrieved on: 
Tuesday, February 7, 2023
Data Management, Biotechnology, Technology, Health, Pharmaceutical, Oncology, Health Technology, Research, Software, Genetics, Science, Strategic management, Library, Laboratory, Genomics, Workflow, Fusion, CGW, NGS, Data analysis, RNA, Senior, Arima, Neoplasm, Vaccine, Pierian Spring

Under the terms of the agreement, Velsera will integrate Arima Genomics’ targeted next-generation sequencing (NGS) testing pipelines into the Pierian Clinical Genomics Workspace (CGW), the leading cloud-based platform that provides clinical labs more streamlined and accurate NGS data analysis, interpretation, and reporting.

Key Points: 
  • Under the terms of the agreement, Velsera will integrate Arima Genomics’ targeted next-generation sequencing (NGS) testing pipelines into the Pierian Clinical Genomics Workspace (CGW), the leading cloud-based platform that provides clinical labs more streamlined and accurate NGS data analysis, interpretation, and reporting.
  • The combined solution will enable clinical laboratories to more easily implement sample-to-answer Arima gene fusion testing, helping them identify gene fusions and other structural variants.
  • “Adopting new NGS technologies and instituting new protocols for clinical genomic interpretation and reporting is time-consuming and challenging,” said Chris Roberts, Senior Vice President, Corporate Strategy at Arima Genomics.
  • “We look forward to integrating Arima Genomics’ gene fusion detection technology into our Clinical Genomics Workspace platform.

New Company, Velsera, Represents Summa Equity's Vision to Improve Global Health Outcomes

Retrieved on: 
Thursday, January 12, 2023
Environment, Pharmaceutical, Research, Oncology, Sustainability, Software, Finance, Medical Devices, Environmental, Social and Governance (ESG), Genetics, Professional Services, Science, Technology, Clinical Trials, Data Analytics, Biotechnology, Health, Health Technology, Unisys, Ecosystem, Algorithm, UN, Calyx, IQVIA, Laboratory, Medical imaging, Precision medicine, Machine learning, Knowledge, Health, AI, Conference, Informatics, Seven Bridges, PCR, Patient, Research, Data analysis, Innovation, Acquisition, Summa, Pharmaceutical industry, Capgemini, Pierian Spring, Parexel

The vision for Velsera is supported by thematic-focused impact fund Summa Equity (“Summa”).

Key Points: 
  • The vision for Velsera is supported by thematic-focused impact fund Summa Equity (“Summa”).
  • The promise of precision medicine is held back by barriers across routine health practice and discovery.
  • Velsera sets out to amplify the impact of clinicians, researchers and scientists for the benefit of patients around the world.
  • Velsera unites these companies to advance and bring together their missions which are centered around improving health globally through multi-omics and insights.

Pierian Selected by PreCheck Health Services to Support Hereditary Cancer Testing for Providers and Patients

Retrieved on: 
Tuesday, December 6, 2022
Oncology, Data Management, Health, Technology, Genetics, Software, General Health, Cancer, NGS, Sickle Cell Anemia, a Molecular Disease, CAP, Health, DNA sequencing, Patient, TSA PreCheck, A4M, Collection, Precision medicine, Cardiovascular disease, Somatic mutation, Real-time, CLIA, Neoplasm, Genomics, Organization, Cystic fibrosis, Machine learning, Hospital Insurance and Diagnostic Services Act, Insurance, Algorithm, Risk, Pharmaceutical industry, Medical imaging, Illumina, Pierian Spring

Pierian, a global leader in advanced clinical genomics technology and services, announced a collaboration to support PreCheck Health Services, a CLIA-registered, CAP-accredited high complexity laboratory, in providing cancer-related genomic testing programs for medical practices and patients.

Key Points: 
  • Pierian, a global leader in advanced clinical genomics technology and services, announced a collaboration to support PreCheck Health Services, a CLIA-registered, CAP-accredited high complexity laboratory, in providing cancer-related genomic testing programs for medical practices and patients.
  • PreCheck, an experienced laboratory in molecular diagnostic testing, leveraged Pierians industry-leading expert services to accelerate the launch of its new NGS offerings.
  • Services included validation of two Illumina assays: TruSight Oncology 500 for testing specific tumors and TruSight One Expanded for hereditary cancer risk.
  • PreCheck is initially incorporating hereditary cancer testing, also called germline testing, into its regional services for South Florida providers.

PreCheck Health Services Showcases New Hereditary and Somatic Cancer Testing Capabilities at the A4M World Congress with Support From Pierian

Retrieved on: 
Tuesday, November 29, 2022
Sickle Cell Anemia, a Molecular Disease, Hospital Insurance and Diagnostic Services Act, Public health, DNA sequencing, Genomics, Multimedia, Machine learning, Health, Physician, Patient, CGW, Laboratory, Cancer, Classification, TSA PreCheck, Somatic mutation, Precision medicine, NGS, CAP, Algorithm, Medicine, Medical imaging, Pharmaceutical industry, Pierian Spring, Illumina

By supporting hereditary cancer testing, patients can now benefit from the advantages of NGS to enable more precise cancer diagnosis.

Key Points: 
  • By supporting hereditary cancer testing, patients can now benefit from the advantages of NGS to enable more precise cancer diagnosis.
  • Their first two NGS offerings are based on Illumina's TruSight Hereditary Cancer and TruSight Oncology 500 panels.
  • PreCheck Health Services will be exhibiting at the 30th annual A4M World Congress from December 9th to 11th in Las Vegas, NV at booth #3102.
  • PreCheck Health Services will be showcasing their newly validated cancer panels and offering the attendees detailed sample reports from the Pierian Clinical Genomics Workspace (CGW).

Pierian® and P4 Diagnostix® Collaborate to Help Physician-Owned Laboratories

Retrieved on: 
Tuesday, October 18, 2022
Software, Oncology, General Health, Health, Data Management, Health Technology, Technology, Genetics, Physician, Annual conferences, Informatics, Pathology, Conference, Pols, Machine learning, Laboratory, P4, Genomics, Patient, Gastroenterology, Multimedia, Urology, Cancer, Partnership, Technology, Precision medicine, Industry, NGS, Health, Environment, Algorithm, Pharmaceutical industry, Medicine, Pierian Spring

Pierian , a global leader in advanced clinical genomics technology and services, is pleased to announce an exciting partnership with P4 Diagnostix , a leading-edge network of nationally recognized laboratories.

Key Points: 
  • Pierian , a global leader in advanced clinical genomics technology and services, is pleased to announce an exciting partnership with P4 Diagnostix , a leading-edge network of nationally recognized laboratories.
  • Our collaboration with P4 will help more physician-owned laboratories internalize clinical NGS, increasing patient access to testing and actionable results, states Lindsay Mateo, Chief Business Officer at Pierian.
  • Learn More: Visit Pierian and P4 Diagnostix at booth #107 from Nov. 10-12 at the Large Urology Group Practice Association (LUGPA) Annual Conference in Chicago, IL.
  • P4 is made up of these industry-leading companies: Theranostix, Long Island Pathology, Platinum Pathology, Metamark Laboratories, and P4 Clinical.

P4 Diagnostix® Partners with Pierian to Launch Somatic Testing

Retrieved on: 
Wednesday, September 28, 2022
Health, Precision medicine, Laboratory, Illumina, Algorithm, Machine learning, Organization, Population, Partnership, Patient, Physician, Doctor of Philosophy, Pathology, Genomics, Prostate cancer, Multimedia, Informatics, Phosphorus, Medical imaging, Medicine, P4, Pierian Spring

INDIANAPOLIS, Sept. 28, 2022 /PRNewswire/ -- P4 Diagnostix®, a network of nationally recognized laboratories ("P4"), will be partnering with Pierian, a global leader in advanced clinical genomics technology and services, to launch somatic testing for prostate cancer patients.

Key Points: 
  • INDIANAPOLIS, Sept. 28, 2022 /PRNewswire/ -- P4 Diagnostix, a network of nationally recognized laboratories ("P4"), will be partnering with Pierian, a global leader in advanced clinical genomics technology and services, to launch somatic testing for prostate cancer patients.
  • Using the Illumina TruSight Oncology 500 cancer panel, P4 and Pierian willexpand P4's Urology NGS services to incorporate somatic testing which will complement P4's current germline testing product, UroSeq.
  • Since 2020, P4 has worked with urology practices nationwide to incorporate germline testing into their post-prostate biopsy workflow.
  • P4 is made up of these industry-leading companies: Theranostix, Long Island Pathology, Platinum Pathology, Metamark Laboratories and P4 Clinical.

Genome Medical and Pierian Announce Collaboration to Optimize Genomic Testing Programs

Retrieved on: 
Tuesday, September 20, 2022
Science, Other Science, Biotechnology, Research, General Health, Health, Genetics, Other Health, Health, Â, Digital, Precision medicine, Laboratory, Algorithm, Machine learning, Genetic counseling, Genome, Goldman Sachs, Cancer, Patient, CEO, Family, Fenwick & West, Genomics, Rock Health, RISE, Education, Medicine, Antibiotics, Medical device, Vaccine, Pharmaceutical industry, Pierian Spring

Genome Medical and Pierian are working together to efficiently identify patients who may benefit from genomic testing and an enhanced clinical genomics workflow.

Key Points: 
  • Genome Medical and Pierian are working together to efficiently identify patients who may benefit from genomic testing and an enhanced clinical genomics workflow.
  • For physician-owned or -managed service organizations, Pierian and Genome Medical deliver a streamlined path to in-house, high-quality precision medicine programs that provide recommended and appropriate care to all patients who meet national standards for genomic testing.
  • Genome Medical, the leading genomic care delivery company, is personalizing health care for all through on-demand access to genetic insights and genomic medicine.
  • Pierian is a partner in precision medicine, enabling clinicians and medical facilities to advance clinical genomics programs and modernize patient care.

Syapse and Pierian Announce Genomics Collaboration to Power Precision Oncology

Retrieved on: 
Tuesday, June 14, 2022
Biomarker, NGS, Precision medicine, Program, MBA, CEO, Partnership, Solution, Health, GLOBE, Patient, Genetics, Genetic testing, Oncology, SAN, MD, Industry, AdventHealth, Genomics, Fear, LHN, Cancer, Medical imaging, Medicine, Pierian Spring, Central Florida

Pierian partners with clinicians and medical facilities worldwide to establish high-quality clinical genomics programs and a global sharing network.

Key Points: 
  • Pierian partners with clinicians and medical facilities worldwide to establish high-quality clinical genomics programs and a global sharing network.
  • Syapse is a company dedicated to extinguishing the fear and burden of oncology and other serious diseases by advancing real-world care.
  • Pierian is a partner in precision medicine, enabling clinicians and medical facilities to advance clinical genomics programs and modernize patient care.
  • With advanced interpretation technology connected to the most comprehensive genomic knowledge base, Pierian empowers providers with genomic insights to fulfill the promise of precision care.

Educate 360 Professional Training Partners Acquires Pierian Data

Retrieved on: 
Tuesday, May 4, 2021
Video game consoles, Ancient Greek poetry, Orpheus, Pierian Spring, Xbox 360

b'BOSTON, May 4, 2021 /PRNewswire/ --Educate 360 Professional Training Partners (Educate 360) today announced the acquisition of Pierian Data, Inc., a leading provider of high-quality technology training, with a focus on Python programming language courses, data science courses, and machine learning courses.

Key Points: 
  • b'BOSTON, May 4, 2021 /PRNewswire/ --Educate 360 Professional Training Partners (Educate 360) today announced the acquisition of Pierian Data, Inc., a leading provider of high-quality technology training, with a focus on Python programming language courses, data science courses, and machine learning courses.
  • The acquisition will allow Educate 360 to expand its capabilities to make a broader impact in helping individuals and companies have the right skills and talent in a digitally transforming environment.\nThe CEO of Educate 360, Jason Cassidy, commented: "We are incredibly excited to have Pierian Data as part of Educate 360.
  • "\nPierian founder Jose Portilla, shared his thoughts as well: "I am excited for the next phase of Pierian Data\'s growth with Educate 360.
  • Jose will stay on with Educate 360 as Head of Data Science.\nEducate 360, a portfolio company of investment funds managed by Morgan Stanley Capital Partners, is the professional training partner of choice to improve organizational efficiency and effectiveness, increase cross-functional alignment, and drive results.